Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of HK241 Nebulized Inhalation in Adult Bronchiectasis with Pseudomonas aeruginosa Infection
ChiCTR2500113458Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of amikacin in bronchiectasis and Pseudomonal infection (3 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Change in Pseudomonas aeruginosa (PA) burden in sputum culture from baseline. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
amikacin
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on ChiCTR2500113458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113458.